Index | Nasdaq Biotechnology |
Investment focus | Aktien, USA, Gesundheitswesen |
Fund size | CHF 32 m |
Total expense ratio | 0,35% p.a. |
Replication | Physical (Optimized sampling) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | Nein |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in CHF) | 18,01% |
Inception/ Listing Date | 5. März 2018 |
Distribution policy | Distributing |
Distribution frequency | Semi annually |
Fund domicile | Irland |
Fund Provider | iShares |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | State Street Fund Services (Ireland) Limited |
Investment Advisor | |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Deloitte |
Fiscal Year End | 31. Mai |
Swiss representative | BlackRock Asset Management Schweiz AG |
Swiss paying agent | State Street Bank International GmbH, Munich, Zurich Branch |
Germany | 30% Teilfreistellung |
Switzerland | ESTV Reporting |
Austria | Meldefonds |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | Bank of New York Mellon|Euroclear|JP Morgan|State Street Bank |
Securities lending | Yes |
Securities lending counterparty | Barclays Bank Plc|Barclays Capital Securities Ltd.|BNP Paribas Arbitrage SNC|BNP Paribas SA|Citigroup Global Markets Ltd|Citigroup Inc|Credit Suisse Securities (Europe) Ltd.|Deutsche Bank AG|Goldman Sachs International|HSBC Bank Plc|J.P. Morgan Securities Plc|JP Morgan Chase & Co|Macquarie Bank Limited|Merrill Lynch International|Morgan Stanley & Co. International Plc|Nomura International Plc|Skandinaviska Enskilda Banken AB|Societe Generale SA|The Bank of Nova Scotia|UBS AG |
Amgen, Inc. | 8,40% |
Gilead Sciences, Inc. | 8,21% |
Regeneron Pharmaceuticals | 8,06% |
Vertex Pharmaceuticals, Inc. | 8,03% |
Moderna, Inc. | 4,20% |
AstraZeneca PLC ADR | 4,07% |
Biogen, Inc. | 3,24% |
Illumina | 2,25% |
Alnylam Pharmaceuticals | 1,94% |
BioMarin Pharmaceutical | 1,70% |
USA | 83,22% |
Irland | 1,38% |
Deutschland | 1,03% |
Sonstige | 14,37% |
Gesundheitswesen | 88,51% |
Sonstige | 11,49% |
YTD | +9.96% |
1 month | +7.93% |
3 months | +3.72% |
6 months | +19.84% |
1 year | +7.78% |
3 years | -4.24% |
5 years | +24.49% |
Since inception (MAX) | +22.77% |
2023 | -5.12% |
2022 | -9.61% |
2021 | +3.38% |
2020 | +14.54% |
Aktuelle Ausschüttungsrendite | 0,38% |
Dividends (last 12 months) | CHF 0,02 |
Period | Dividend in CHF | Dividend yield in % |
---|---|---|
1 Jahr | CHF 0,02 | 0,41% |
2023 | CHF 0,02 | 0,39% |
2022 | CHF 0,03 | 0,41% |
2021 | CHF 0,02 | 0,26% |
2020 | CHF 0,01 | 0,21% |
Volatility 1 year | 18.20% |
Volatility 3 years | 23.77% |
Volatility 5 years | 25.92% |
Return per risk 1 year | 0.28 |
Return per risk 3 years | 0.08 |
Return per risk 5 years | 0.26 |
Maximum drawdown 1 year | -11.74% |
Maximum drawdown 3 years | -30.89% |
Maximum drawdown 5 years | -30.89% |
Maximum drawdown since inception | -30.89% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | OM3E | - - | - - | - |
London Stock Exchange | USD | BTEE | BTEE LN INAVBTDU | BTTE.L |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Nasdaq US Biotechnology UCITS ETF | 442 | 0.35% p.a. | Accumulating | Sampling |
Invesco Nasdaq Biotech UCITS ETF | 317 | 0.40% p.a. | Accumulating | Swap-based |